


11<sup>th</sup> International Conference on

# CANCER STEM CELLS AND ONCOLOGY RESEARCH

June 11-13, 2018 | Dublin, Ireland



**Allied Academies**

40 Bloomsbury Way, Lower Ground Floor  
London, United Kingdom, WC1A 2SE

<http://cancerstemcells.alliedacademies.com/>

**For Queries**

Contact: Program Manager

Email: <http://cancerstemcells.alliedacademies.com/>

Office Ph: +1-888-843-8169

Toll No: +1-800-216-6499 (USA & Canada)



## Keynote Forum

**Title: BCL-XL directly modulates RAS signalling to favour cancer cell stemness**

**Philippe Juin**, CRCINA, France

**Title: Polyploid Giant Cancer Cells may Represent a Somatic Equivelant of Blastomere**

**Jinsong Liu**, The University of Texas M. D. Anderson Cancer Center, USA

**Title: Inflammatory cytokines, induced by ionizing radiation, reprogram non-tumorigenic cancer cells into cancer stem cells in breast cancer**

**Chann Lagadec**, INSERM, France

**Title: Targeting Notch4 in ovarian cancer results in decreased number of cancer stem cells and increased survival when used in combination with cisplatin in pre-clinical models**

**Elaine M. Hurt**, MedImmune, USA

**Title: Identification of cancer stem cell (CSC) in its spatial context and immune environment through the application of cognitive and machine learning**

**Ralf Huss**, Definiens, Germany

**Title: Replication stress response in CSCs: molecular mechanisms and therapeutic implication**

**Ilio Vitale**, Regina Elena National Cancer Institute, Rome, Italy

**Title: Cancer Stem Cells: Engine of Therapy Resistance & Seeds of Tumor Recurrence**

**Dean G. Tang**, Roswell Park Cancer Institute, USA

**Title: Integrated analyses identify a poor-prognosis subtype of hepatocellular carcinoma regulated by a core microRNA regulatory circuitry**

**Jiangwen Zhang**, The University of Hong Kong, China

**Title: Angiogenin and plexin-B2 inhibition sensitizes prostate cancer stem cells to chemotherapy**

**Guo-fu Hu**, Molecular Oncology Research Institute, Tufts Medical Center, USA

**\*\*Keynote Slot Available\*\***

## \*\*Speaker Contribution\*\*

**Title: Metakaryotic cancer stem cells are constitutively resistant to x-rays and chemotherapeutic agents but sensitive to many common drugs: first clinical trial shows effectiveness of a metakaryocide against stem cells in a series of human pancreatic tumors**

**William G. Thilly**, Massachusetts Institute of technology (MIT), USA

**Title: Quiescent epithelial stem cells evade immune surveillance**

**Judith Agudo**, Dana-Farber Cancer Institute, Harvard Medical School, USA

**Title: The constitution of Cancer tissues: the properties and implication of cancer stem cells derived from patients' samples**

**Xianming Mo**, Sichuan University, China

**Title: Drug resistant stem cells: Models for targeted therapy of breast cancer**

**Nitin Telang**, Cancer Prevention Research Program, Palindrome Liaisons Consultants, USA

**Title: Inhibitor of apoptosis proteins determine glioblastomas stem-like cells fate in an oxygen-dependent manner**

**Aur lie Tchoghandjian**, Aix-Marseille University, France

**Title: Magnetic Nanocrystals and magnetic hyperthermia to tackle cancer stem cells**

**Teresa Pellegrino**, Italian Institute of Technology, Italy

**Title: Epithelial cell adhesion molecule (EpCAM) as a CSC marker in prostate cancer chemo-/radio-resistance**

**Yong Li**, University of New South Wales (UNSW), Australia

**Title: Released-active antibodies: Breakthrough concept of antibodies-based therapeutics**  
**Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma**

**Roberto Crocchiolo**, San Raffaele Hospital, Milano, Italy

**Title: EGFR sorting in lung cancer: “Smells like a sortilin spirit”**

**Thomas Naves**, Université de Limoges, France

**Title: Unravelling mesenchymal stem cell - prostate cancer interactions during metastatic progression**

**Sharon A Glynn**, National University of Ireland Galway, Ireland

**\*\*Speaker Slot Available\*\***

**Title: Targeting CHK1 for eradicating colorectal cancer stem cells**

**Gwenola Manic**, Regina Elena National Cancer Institute, Rome, Italy

**Title: Targeting CRC-SC for differentiation – a 3D screening system for differentiation therapies**

**Mehreen Ahmed**, University of Nottingham, UK

**Title: Circulating Epithelioid Cells and Personalized Medicine: the good, the bad and the ugly ... and many others**

**Claire Acquaviva**, Centre de Recherche en Cancérologie de Marseille (CRCM), France

**Title: Role of miRNAs and YAP in the promotion of colorectal cancer stem cell self-renewal by the tight junction protein claudin-2**

**Frederic Hollande**, The University of Melbourne, Australia

**Title: Circulating tumor cell ex-vivo culture from patient with colorectal cancer display heterogeneity and cancer stem cell hallmarks**

**Julie Pannequin**, Institut De Genomique Fonctionnelle, France

**Title: DNA Damage Responses in Ovarian Cancer Stem Cells**

**Qi-En Wang**, The Ohio State University Wexner Medical Center, USA

**Title: Key regulators of symmetrical and asymmetrical division of epithelial cells in prostate development and tumorigenesis**

**Wei-Qiang Gao**, Shanghai Jiao Tong University, China

**Title: Phage display library screening identifies novel binding peptides that preferentially target castration-resistant PSA-/lo prostate cancer stem cells**

**Kiera Rycaj**, Roswell Park Cancer Institute, USA

**Title: NFATc2-SOX<sub>2</sub> coupling supports cancer stem cells and mediates drug resistance of lung adenocarcinoma**

**Maria Pik Wong**, The University of Hong Kong, China

**Title: Drug resistant stem cells: Models for targeted therapy of breast cancer**

**Nitin Telang**, Cancer Prevention Research Program, Palindrome Liaisons Consultants, USA

**Title: SETMAR in Glioblastoma: Splice variants and feedback network in controlling target genes expression**

**Corinne Augé-Gouillou**, University of Tours, France

**Title: Neurotrophins receptors : New aggressiveness markers in Glioblastoma**

**Barbara Bessette**, Université de Limoges, France

**\*\*Speaker Slot Available\*\***

**Title: Modelling Cancer Stem Cells on FiSS Platform**

**Subhra Mohapatra**, University of South Florida, USA

**Title: miR-148a inhibits colon cancer stem cell properties by targeting Pregnane X- Receptor signaling**

**Jean Marc Pascussi**, University of Montpellier, France

**Title: Development of novel miR-129 mimic with enhanced therapeutic potential to eliminate resistant colon cancer stem cells**

**Jingfang Ju**, Stony Brook University, USA.

**Title: Increasing telomerase in human cancer stem cells by novel compounds enhanced the sensitivity of the cells to certain anti-cancer agents**

**Esther Priel**, Ben-Gurion University of the Negev, Israel

**Title: Targeting the multidrug transporter Patched potentiates chemotherapy efficiency in vitro and in vivo**

**Isabelle Mus-Veteau**, Institut de Pharmacologie Moléculaire et Cellulaire, France

**Title: hTERT High Numb-/low state enriches a castration resistant prostate cancer cell subpopulation with tumor initiating capacity**

**Helen He Zhu**, Shanghai Jiao Tong University, China

**Title: TGF- $\beta$  signaling is a novel therapeutic target for treating metastatic cancers acquired by EMT and cancer stemness**

**Seong-Jin Kim**, Seoul National University, Korea

**Title: Molecules Targeting Cancer Stem Cells**

**Maithili A. Athavale**, Sathgen Biotech, Mumbai, India

**Title: Epithelial cell adhesion molecule (EpCAM) as a CSC marker in prostate cancer chemo-/radio-resistance**

**Yong Li**, University of New South Wales (UNSW) Sydney, Australia

**Title: Autonomous and reciprocal mechanisms drive cellular heterogeneity among stem-like cancer cells in oral tumors**

**Sandeep Singh**, National Institute of Biomedical Genomics, India

**\*\*Speaker slots Available@ Cancer Stem Cells 2018\*\***

**Title: A design of conventional electron cone technique for delivering total skin electron therapy on Mycosis Fungoides Patients**

**Jia-Ming Wu**, People's Hospital, Hunan, China

**Title: CD44 variant 6 (CD44v6) as a cancer stem cell biomarker in prostate cancer progression and chemo-/radio-resistance**

**Jie Ni**, University of New South Wales (UNSW), Australia

**Title: Involvement of N-, E-cadherin and beta-catenin in progression of intracranial meningioma**

**Anja Bukovac**, Croatian Institute for Brain Research, School of Medicine University of Zagreb, Croatia

**Title: In-vivo and in-vitro impact of miR-21 and miR-126 in the suppression of metastasis and invasion in breast cancer**

**Sina Taefehshokr**, Islamic Azad University, Tabriz, Iran

**Title: Targeting of breast cancer stem cells with the innovative use of cell-penetrating natural monoclonal autoantibodies**

**Theodora Stivarou**, Hellenic Pasteur Institute, Greece

**Title: Glutathione S-transferase P1 supports cancer stem cell phenotypes of lung adenocarcinoma**

**Siqi Wang**, The University of Hong Kong, China

**Title: Deciphering the role of A2B5 in glioblastomas**

**N Baeza-Kallee**, Aix Marseille Université, INSERM, France

**Title: Isolation, structural elucidation, and bioactivity studies of leaf extract of Vernonia Amygdalina**

**Muluye Melak Zenebe**, University of Gondar, College of Natural Sciences, Ethiopia

**\*\*Speaker Slot Available\*\***

**NOTE: Program Schedule is subject to change with final allotment of the speaker slots**